Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Canine Lymphocyte activating 3 (LAG3) ELISA Kit-Sandwich

Name: Canine Lymphocyte activating 3 (LAG3) ELISA Kit-Sandwich
SKU: EK10F822
Rating: 5 (1 reviews)

Cat. No.EK10F822

Product TypeAnimal Immunoassay Kits

Size

Inquiry Now Add to Basket

Product Overview

BioVenic Canine LAG3 ELISA Kit-Sandwich is designed for the quantitative determination of Canine LAG3 in serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids using a Sandwich ELISA method. For research use only.

Specifications

Assay Type ELISA-Sandwich

Specificity The assay kit is specific for Canine LAG3.

Target Species Canine

Species Reactivity Canine

Detection Range 0.2-10 ng/mL

Sensitivity 0.03 ng/mL

Reproducibility Intra-Assay: CV < 10%; Inter-Assay: CV < 10%

Assay Time Around 180 min

Sample Requirement Serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids.

Target Information

Lymphocyte activating 3 is encoded by the LAG3 gene in dogs. It has emerged as an eminent target in the development of cancer treatment and holds substantial prognostic value.

Target/Biomarker Canine LAG3

Target Synonym lymphocyte activating 3; lymphocyte activation gene 3 protein; lymphocyte-activation gene 3

Gene ID 486720

UniProt ID A0A8C0TR30

Shipping and Storage

This product is shipped with gel ice packs. It is recommended to store at 2-8 °C (Up to 6 months).

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

Lecocq, Q. et al. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: Third time's a charm. International journal of molecular sciences. 2020, 22: 1867.